Extracorporeal Magnetic Innervation Plus Pelvic Floor Muscle Training for Premature Ejaculation
Effects of Extracorporeal Magnetic Innervation Plus Pelvic Floor Muscle Training for Premature Ejaculation: A Randomized Controlled Trial
1 other identifier
interventional
44
1 country
1
Brief Summary
This single-center, prospective, parallel-group randomized controlled trial evaluated whether extracorporeal magnetic innervation (ExMI) added to pelvic floor muscle training (PFMT) improves pelvic floor muscle function and premature ejaculation symptoms compared with PFMT alone in men with premature ejaculation. Participants were assessed at baseline, week 4, and week 8 using real-time suprapubic ultrasonography and validated patient-reported outcome measures.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2019
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 14, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 8, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 8, 2023
CompletedFirst Submitted
Initial submission to the registry
January 27, 2026
CompletedFirst Posted
Study publicly available on registry
February 4, 2026
CompletedSeptember 11, 2026
September 1, 2026
3.3 years
January 27, 2026
September 9, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Pelvic Floor Muscle Displacement (mm) Assessed by Real-Time Suprapubic Ultrasonography
Pelvic floor muscle activation was assessed by measuring displacement of the caudal border of the prostate from rest to maximal voluntary pelvic floor contraction using real-time suprapubic ultrasonography. Three contractions were recorded and averaged. Greater displacement indicates greater pelvic floor muscle activation.
Baseline, Week 4, and Week 8
Pelvic floor muscle endurance (seconds) on real-time suprapubic ultrasonography
Pelvic floor muscle endurance was defined as the duration, in seconds, for which the participant could maintain maximal visible pelvic floor elevation during voluntary contraction under real-time suprapubic ultrasonography. Longer duration indicates greater pelvic floor muscle endurance.
Baseline, Week 4 and Week 8
Secondary Outcomes (6)
Premature Ejaculation Diagnostic Tool (PEDT)
Baseline, Week 4 and Week 8
Brief Sexual Function Inventory (BSFI)
Baseline, Week 4 and Week 8
Five-Item International Index of Erectile Function (IIEF-5)
Baseline, Week 4 and Week 8
World Health Organization Quality of Life-BREF (WHOQOL-BREF) Total Score
Baseline, Week 4 and Week 8
Exploratory WHOQOL-BREF Sexual Satisfaction Item
Baseline, Week 4, and Week 8
- +1 more secondary outcomes
Study Arms (2)
Arm A - Pelvic Floor Muscle Training (PFMT)
ACTIVE COMPARATORParticipants received structured education about pelvic floor anatomy and function and completed an 8-week progressive home-based pelvic floor muscle training program. The program included both slow and fast pelvic floor muscle contractions performed in five sets daily.
Arm B - Pelvic Floor Muscle Training (PFMT) + Extracorporeal Magnetic Innervation (ExMI)
EXPERIMENTALParticipants completed the same 8-week progressive pelvic floor muscle training program as Arm A and additionally received chair-based extracorporeal magnetic innervation twice weekly for 8 weeks, for a total of 16 sessions.
Interventions
Participants performed five sets of pelvic floor muscle exercises daily for 8 weeks. Each set included slow and fast contractions. The number of each type of contraction was progressively increased from 10 in week 1, to 20 in week 2, 30 in week 3, and 40 in week 4. During weeks 5-8, each set included 50 slow and 50 fast contractions. Correct pelvic floor contraction was taught and verified using real-time ultrasonography.
Extracorporeal magnetic innervation was delivered using the EMD E-6000 MAGTHER system with the participant seated on the treatment chair. Treatment was administered twice weekly for 8 weeks, for a total of 16 sessions. Each session consisted of 10 minutes of intermittent stimulation at 10 Hz, followed by a 1-minute rest period and 10 minutes of intermittent stimulation at 50 Hz. Stimulation intensity was increased to the highest comfortably tolerated level.
Eligibility Criteria
You may qualify if:
- Male adults with premature ejaculation diagnosed by a specialist physician
- Sexually active
- Literate and able to understand study instructions
- Voluntary participation with informed consent
- Able to cooperate with study assessments and pelvic floor muscle training
You may not qualify if:
- Medication use or medical conditions likely to affect erection or ejaculation
- Metabolic, chronic systemic, psychiatric, or significant cardiovascular disorders
- Alcohol or substance dependence
- Peyronie's disease
- Chronic prostatitis
- Urethritis
- Active urinary tract infection
- Documented abnormal semen quality
- Mental or cognitive problems preventing adequate cooperation with study procedures
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Bolu Abant Izzet Baysal University, Faculty of Health Sciences
Bolu, Merkez, 14030, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
January 27, 2026
First Posted
February 4, 2026
Study Start
October 14, 2019
Primary Completion
February 8, 2023
Study Completion
March 8, 2023
Last Updated
September 11, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will not share
There is no plan for public sharing of individual participant data. The original informed consent and ethics approval did not include public deposition of participant-level data. De-identified data may be considered for sharing on reasonable request, subject to institutional and ethical requirements.